Prosight Management’s Horizon Therapeutics HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-81,035
Closed -$8.84M – 50
2023
Q1
$8.84M Sell
81,035
-8,965
-10% -$991K 4.19% 9
2022
Q4
$10.2M Sell
90,000
-213,000
-70% -$17.7M 5.59% 6
2022
Q3
$18.8M Buy
+303,000
New +$21.2M 10.05% 2

Other funds holding HZNP

Prosight Management's HZNP Position: Q2 2023 in Review

Prosight Management sold out of Horizon Therapeutics (HZNP) in Q2 2023, closing a stake of 81,035 shares — an estimated $8.84M sold.

Prosight Management first reported a position in HZNP in Q3 2022 and held it in 3 quarters. The position peaked at $18.8M in Q3 2022. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Prosight Management reported no remaining Horizon Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prosight Management sold 81,035 Horizon Therapeutics shares in Q2 2023, an estimated $8.84M.
  • Prosight Management first reported a position in Horizon Therapeutics in Q3 2022 and held it in 3 quarters.
  • Prosight Management's Horizon Therapeutics position peaked at $18.8M in Q3 2022.
  • 517 funds tracked by Wall St. Rank held Horizon Therapeutics as of Q2 2023.

Based on Prosight Management's 13F filing for Q2 2023, filed 14 Aug 2023.